INVO Fertility, Inc.IVFEarnings & Financial Report
INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.
Revenue
$1.8M
Gross Profit
$974.9K
Operating Profit
$-1.9M
Net Profit
$-2.2M
Gross Margin
53.1%
Operating Margin
-100.9%
Net Margin
-122.2%
YoY Growth
481.4%
EPS
$-22.39
INVO Fertility, Inc. Q2 FY2024 Financial Summary
INVO Fertility, Inc. reported revenue of $1.8M (up 481.4% YoY) for Q2 FY2024, with a net profit of $-2.2M (down 0.2% YoY) (-122.2% margin). Cost of goods sold was $861.6K, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-2.2M |
| Gross Margin | 53.1% |
| Operating Margin | -100.9% |
| Report Period | Q2 FY2024 |
INVO Fertility, Inc. Annual Revenue by Year
INVO Fertility, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $6.6M |
| 2023 | $3.0M |
| 2022 | $822.2K |
INVO Fertility, Inc. Quarterly Revenue & Net Profit History
INVO Fertility, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $1.8M | +22.6% | $-2.6M | -150.5% |
| Q2 FY2025 | $1.9M | +1.5% | $-5.3M | -283.6% |
| Q1 FY2025 | $1.6M | +4.1% | $-17.4M | -1060.1% |
| Q4 FY2024 | $1.7M | +24.1% | $-3.6M | -211.3% |
| Q3 FY2024 | $1.4M | +47.0% | $-1.6M | -113.8% |
| Q2 FY2024 | $1.8M | +481.4% | $-2.2M | -122.2% |
| Q1 FY2024 | $1.6M | +352.9% | $-1.6M | -101.3% |
| Q4 FY2023 | $1.4M | +396.8% | $-2.0M | -144.4% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.6M | $1.8M | $1.4M | $1.7M | $1.6M | $1.9M | $1.8M |
| YoY Growth | 396.8% | 352.9% | 481.4% | 47.0% | 24.1% | 4.1% | 1.5% | 22.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $18.5M | $17.3M | $17.8M | $17.0M | $46.4M | $31.7M | $19.3M | $18.8M |
| Liabilities | $17.6M | $17.3M | $16.4M | $17.0M | $26.2M | $24.4M | $16.7M | $13.0M |
| Equity | $892825 | $10155 | $1.4M | $-23316 | $12.7M | $3.3M | $2.6M | $5.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-714883 | $-260557 | $-1.5M | $-640807 | $-617379 | $-3.5M | $-1.7M | $-1.8M |